Celgene Continues Support In Latest Financing Round For ARMO BioSciences

8/31/17

Quick Take

Biopharmaceutical company Celgene (CELG) has participated in the $67 million Series C-1 financing round of ARMO BioSciences.

ARMO is a clinical stage company developing a pipeline of immunotherapy-based treatments that activate the immune system to fight a variety of cancers.

Celgene is an active investor in privately held biopharmaceutical companies as it aggressively pursues deep relationships with companies developing the latest innovations in healthcare.

READ FULL ARTICLE HERE

It's on us. Share your news here.

Submit your stories and articles to citybizlist today.